| GTO ID | GTC3346 |
| Trial ID | NCT05743335 |
| Disease | COVID-19 | Viral Infectious Disease |
| Therapy | mRNA vaccine |
| Treatment | JCXH-221 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A PHASE 1/2 STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A BROADLY PROTECTIVE mRNA VACCINE JCXH-221 AGAINST SARS-CoV-2 INFECTION AND DISEASES |
| Year | 2023 |
| Country | United States |
| Company sponsor | Immorna Biotherapeutics, Inc. |
| Other ID(s) | JCXH-221-001 |
| Vector information | |||
|
|||
| Cohort1: JCXH-221 | |||||
|
|||||
| Cohort2: Placebo | |||||
|
|||||
| Cohort3: FDA approved COVID-19 Vaccine | |||||
|
|||||